Metabolism of ifosfamide to chloroacetaldehyde contributes to antitumor activity in vivo

Drug Metabolism and Disposition

Volumn 28, Issue 5, 2000, Pages 573-576

  Börner, Kirsten ^a   Kisro, Jens ^a   Brüggemann, Svenja K ^a   Hagenah, Wibke ^a   Peters, Stefan O ^a   Wagner, Thomas ^a  

^a UNIVERSITY OF LÜBECK   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CHLOROACETALDEHYDE; IFOSFAMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CYTOTOXICITY; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; TUMOR CELL CULTURE; TUMOR GROWTH; XENOTRANSPLANTATION;

ACETALDEHYDE; ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; BREAST NEOPLASMS; HUMANS; IFOSFAMIDE; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; PRODRUGS; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

ANIMALIA; MUS MUSCULUS;

EID: 0343415166     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Alarcon RA (1968) Fluorometric determination of acrolein and related compounds with m-aminophenol. Anal Chem 40:1704-1708.
2. Brade WP, Herdrich K and Varini M (1985) Ifosfamide-pharmacology, safety and therapeutic potential. Cancer Treat Rev 12:1-47.
3. Brain EG, Yu LJ, Gustafsson K, Drewes P and Waxman DJ (1998) Modulation of P450-dependant ifosfamide pharmacokinetics: A better understanding of drug activation in vivo. Br J Cancer 77:1768-1776.
4. Bramwell VHC, Mouridsen HT, Santoro A, Blackledge G, Somers R, Verwey J, Dombernowsky P, Onsrud M, Thomas D, Sylvester R and van Oosterom A (1987) Cyclophosphamide versus ifosfamide: Final report of a randomized phase II trial in adult soft tissue sarcomas. Eur J Cancer Clin Oncol 23:311-321.
5. Brüggemann SK, Kisro J and Wagner T (1997) Ifosfamide cytotoxicity on human tumor and renal cells: Role of chloroacetaldehyde in comparison to 4-hydroxyifosfamide. Cancer Res 57:2676-2680.
6. Connors TA, Cox PJ, Farmer PB, Foster AB and Jarman M (1974) Some studies of the active intermediates formed in the microsomal metabolism of cyclophosphamide and isophosphamide. Biochem Pharmacol 23:115-129.
7. DiMaggio JR, Brown R, Baile WF and Schapira D (1994) Hallucinations and ifosfamide-induced neurotoxicity. Cancer 73:1909-1914.
8. Goren MP, Wright RK, Pratt CB and Pell FE (1986) Dechlorethylation of ifosfamide and neurotoxicity. Lancet 2:1219-1220.
9. Heinzel G, Wolaszak R and Thomann P (1993) Pharmacokinetics and Pharmacodynamic Data Analysis System for the PC. Gustav Fischer Stuttgart, Jena, New York.
10. Kaijser GP, Beilnen JH, Bult A and Underberg WJ (1994) Ifosfamide metabolism and pharmacokinetics. Anticancer Res 14:517-531.
11. Kamen BA, Frenkel E and Colvin OM (1995) Ifosfamide: Should the honeymoon be over? J Clin Oncol 13:307-309.
12. Kuchenmeister F, Schmerzer P and Engelhardt G (1998) Genotoxic bifunctional aldehydes produce specific images in the comet assay. Mutat Res 419:69-78.
13. Kurowski V and Wagner T (1993) Comparative pharmacokinetics of ifosfamide, 4-hydroxyifosfamide, chloroacetaldehyde, and 2- and 3-dechloroethylifosfamide in patients on fractionated intravenous ifosfamide therapy. Cancer Chemother Pharmacol 33:36-42.
14. 4-methyldeoxythymidine, using polymerases of varying fidelity. Carcinogenesis (Lond) 5:1165-1171.
15. Skinner R, Sharkey IM, Pearson AD and Craft AW (1993) Ifosfamide, mesna, and nephrotoxicity in children. J Clin Oncol 11:173-190.
16. Sladek NE (1988) Metabolism of oxazaphosphorines. Pharmacol Ther 37:301-355.
17. Sood C and O'Brian PJ (1993) Molecular mechanism of chloroacetaldehyde-induced cytotoxicity in isolated rat hepatocytes. Biochem Pharmacol 46:1621-1626.
18. Spengler SJ and Singer B (1988) Formation of interstrand cross-links in chloroacetaldehyde-treated DNA demonstrated by ethium bromide fluorescence. Cancer Res 48:4804-4806.
19. Wagner T (1994) Ifosfamide clinical pharmacokinetics. Clin Pharmacokinet 26:439-456.
20. Wagner T, Heydrich D, Jork T, Voelcker G and Hohorst HJ (1981) Comparative study on human pharmacokinetics of activated ifosfamide and cyclophosphamide by a modified fluorometric test. J Cancer Res Clin Oncol 100:95-104.
21. Wiedemann GJ, Siemens HJ, Mentzel M, Biersack A, Wössmann W, Knocks D, Weiss C and Wagner T (1993) Effects of temperature on therapeutic efficacy and pharmacokinetics of ifosfamide. Cancer Res 53:4268-4272.
22. Yu LIJ, Drewes P, Gustafsson K, Brain EGC, Hecht JED and Waxman DJ (1999) In vivo modulation of alternative pathways of P-450-catalyzed cyclophosphamide metabolism: Impact on pharmacokinetics and antitumor activity. J Pharmacol Exp Ther 288:928-937.